Somapacitan not checked
Novo Nordisk · NNC0195-0092
FollowEvery change as it happens, and a Monday email
Next date
None yet
Trials
3 active
6 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.”In the company’s words, NCT05723835 on ClinicalTrials.gov
- Tested for
- SGA, Turner Syndrome, Noonan Syndrome, ISS, SGA, Turner Syndrome, Noonan Syndrome, ISS, Short Stature Children Born Small for Gestational Age (SGA)
- Main trialPhase 3
- “The purpose of this study is to find out if somapacitan is safe and how well somapacitan works in children either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Somapacitan is a new growth hormone medicine for treatment of low level of growth hormone. The study will last for about 3 years. During the study, the participants will be treated with somapacitan once a week. Somapacitan can be injected anytime during the day. The study doctor or nurse will show how to inject somapacitan, so that the participant knows how to do it at home.”In the company’s words, NCT05723835 on ClinicalTrials.gov
- Other names
- NNC0195-0092
Other drugs for Turner Syndrome
- LonapegsomatropinAscendis Pharma Endocrinology Division A/S · Phase 3
- InpegsomatropinXiamen Amoytop Biotech Co., Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 7 Jun 2024 | A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 | |
| Phase 3Active, not recruiting | 5 Aug 2024 | A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow | |
| Phase 2Active, not recruiting | 5 May 2021 | A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day | |
| Phase 3Completed | 10 Nov 2021 | A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4) | |
| Phase 3Completed | 17 Nov 2023 | A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day. | |
| Phase 2Completed | 26 Sep 2024 | Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026